Logo

CareDx: Hannah Valantine

Jun 30, 2021

CareDx has appointed Hannah Valantine to its board of directors.

Valantine is a professor of medicine at Stanford and the former NIH CSO for Scientific Workforce Diversity. Prior to joining the NIH, she served as professor of cardiovascular medicine and senior associate dean for diversity and leadership at Stanford. Valantine has partnered with CareDx for several years, including as a principal investigator on publications for the company's AlloMap Heart test, and is one of the researchers behind the original patents for CareDx's AlloSure test.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.